US-based healthcare technology company Medtronic has presented new clinical and real-world data on the MiniMed 780G insulin delivery system.
The latest datasets evaluated the system for younger patients, those not meeting glycaemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations.
The results showed that the propriety meal detection technology supported Time in Range (TIR) outcomes that exceed consensus guidelines of 70%. The system reduces the time spent on hyperglycaemia in both children and adults.
The results were presented at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego, California.
The first study by Sidra Medicine's Dr Goran Petrovski randomly assigned 34 adolescent users into two groups. Some entered a fixed pre-set number of carbs, and some calculated a precise number of carbs for their meals. Participants had lived with diabetes for at least one year and used multiple daily injections or pump therapy prior to the study.
Results showed those using the fixed carb entry maintained international targets for glycaemic control over six months without system modification.
Real-world evidence in 3,543 children aged 15 years or younger in Europe and Latin America with recommended settings of 100mg/dL and two-hour active insulin time demonstrated a TIR of 78%.
A separate analysis of real-world evidence of 2,516 children aged 15 years or younger in Europe showed improved glycaemic performance in SmartGuard technology regardless of baseline glycaemic control.
Real-world analysis of the Medtronic Extended Infusion Set showed that almost half of the participants wore the set for seven days. This data mirrors the US pivotal trial results and delivers a reduced user burden through less frequent infusion set changes.
Dr Petrovski said: "This study shows that a simplified meal management approach with the MiniMed 780G system helped users maintain glycaemic targets while providing forgiveness for inexact carb counts. Clearly, there's more runway for simplification of diabetes management with this system and it's promising for the many patients struggling with meal management."
The MiniMed 780G received CE Mark certification in June 2020 and was FDA-approved in April 2023.
According to a report by GlobalData, the insulin pumps and continuous glucose monitors market was valued at $10.56bn in 2022. GlobalData forecasts that the CGM market will reach $8.4bn by 2030.
